Skip to main content
Nanjing Leads Biolabs Co., Ltd. logo

Nanjing Leads Biolabs Co., Ltd. — Investor Relations & Filings

Ticker · 9887 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 81 across all filing types
Latest filing 2026-04-24 Proxy Solicitation & In…
Country HK Hong Kong
Listing HKEX 9887

About Nanjing Leads Biolabs Co., Ltd.

https://www.leadsbiolabs.com

Nanjing Leads Biolabs Co., Ltd. is a clinical-stage biotechnology company engaged in the integrated discovery, development, and commercialization of innovative antibody-based therapeutics. The company's core focus is on addressing global unmet patient needs across major therapeutic areas, including oncology, autoimmune diseases, and critical illnesses. Utilizing an in-house R&D platform, Leads Biolabs develops novel candidate drugs. Key pipeline assets include bifunctional inhibitors, such as DNTH-212, which targets BDCA2 and BAFF/APRIL for the treatment of autoimmune conditions.

Recent filings

Filing Released Lang Actions
PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 15, 2026
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a proxy form for the Annual General Meeting, providing voting instructions and soliciting appointment of proxies for shareholders. This is part of the materials sent to shareholders to request votes for the AGM, matching the description of a Proxy Solicitation & Information Statement (PSI).
2026-04-24 English
(1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2025 FINAL FINANCIAL REPORT; (3) 2025 ANNUAL REPORT; (4) 2025 PROFIT DISTRIBUTION PLAN; (5) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR; (6) RE-A
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a shareholder circular issued ahead of the Annual General Meeting, containing a notice of meeting, proposed resolutions (board work report, financial report, auditor reappointment, share issuance mandates, amendments to articles, etc.), explanatory statements, and proxy form instructions. These characteristics exactly match a Proxy Solicitation & Information Statement, which provides information and solicits votes for a shareholder meeting.
2026-04-24 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is the formal notice of the company’s Annual General Meeting, sent to shareholders to inform them of resolutions to be considered and to request their attendance or proxy voting. It provides details on meeting date, resolutions (including board reports, financial report, capital mandates, share repurchase mandate, etc.), proxy appointment instructions, and related procedural notes. This aligns with the definition of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings. It is not the Annual Report itself, nor a presentation from the AGM, so it’s classified as PSI.
2026-04-24 English
2025 ANNUAL REPORT
Annual Report Classification · 1% confidence The document is explicitly titled '2025 ANNUAL REPORT' and contains comprehensive sections typical of a full annual report, including a Chairman's Statement, Management Discussion and Analysis (MDA), Corporate Governance Report, Independent Auditor's Report, and full Consolidated Financial Statements (Profit or Loss, Financial Position, Cash Flows, etc.). It is not an announcement of a report, but the report itself. FY 2025
2026-04-24 English
2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Regulatory Filings
2026-04-24 English
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Regulatory Filings Classification · 1% confidence The document is an announcement pursuant to HK Listing Rule 13.51(1) detailing proposed house-keeping amendments to the Company’s articles of association. It is not a full governance report or circular/proxy statement, but a stock-exchange announcement of regulatory changes. It does not present financial results, management changes, dividends, or other specific filings. Therefore the most appropriate classification is a general regulatory announcement (RNS).
2026-04-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.